FFM
VRTX icon

Fullerton Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Fullerton Fund Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-568
Closed -$254K – 160
2026
Q1 		$254K Sell
568
-332
-37% -$155K 0.02% 108
2025
Q4 		$408K Sell
900
-622
-41% -$268K 0.02% 91
2025
Q3 		$596K Buy
+1,522
New +$636K 0.02% 77
2025
Q2 		– Sell
-1,028
Closed -$498K – 129
2025
Q1 		$498K Buy
+1,028
New +$479K 0.03% 83
2024
Q4 		– Sell
-1,153
Closed -$536K – 125
2024
Q3 		$536K Sell
1,153
-56
-5% -$26.9K 0.02% 82
2024
Q2 		$567K Hold
1,209
– – 0.03% 69
2024
Q1 		$505K Buy
+1,209
New +$511K 0.02% 72

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fullerton Fund Management's VRTX Position: Q2 2026 in Review

Fullerton Fund Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 568 shares — an estimated $254K sold.

Fullerton Fund Management first reported a position in VRTX in Q1 2024 and held it in 7 quarters. The position peaked at $596K in Q3 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Fullerton Fund Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fullerton Fund Management sold 568 Vertex Pharmaceuticals shares in Q2 2026, an estimated $254K.
  • Fullerton Fund Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • Fullerton Fund Management's Vertex Pharmaceuticals position peaked at $596K in Q3 2025.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Fullerton Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.